These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22150825)

  • 81. Re-formulating Gehan's design as a flexible two-stage single-arm trial.
    Grayling MJ; Mander AP
    BMC Med Res Methodol; 2019 Jan; 19(1):22. PubMed ID: 30691398
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Optimal adaptive single-arm phase II trials under quantified uncertainty.
    Kunzmann K; Kieser M
    J Biopharm Stat; 2020; 30(1):89-103. PubMed ID: 31023135
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Screening designs for drug development.
    Rossell D; Müller P; Rosner GL
    Biostatistics; 2007 Jul; 8(3):595-608. PubMed ID: 17030589
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Sample size and design considerations for phase II clinical trials with correlated observations.
    Sargent DJ; Sloan JA; Cha SS
    Control Clin Trials; 1999 Jun; 20(3):242-52. PubMed ID: 10357497
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
    Lin CJ; Wason JMS
    Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Designing phase II trials in cancer: a systematic review and guidance.
    Brown SR; Gregory WM; Twelves CJ; Buyse M; Collinson F; Parmar M; Seymour MT; Brown JM
    Br J Cancer; 2011 Jul; 105(2):194-9. PubMed ID: 21712822
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Adaptive clinical trial design.
    Chow SC
    Annu Rev Med; 2014; 65():405-15. PubMed ID: 24422576
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Hypothesis testing for two-stage designs with over or under enrollment.
    Zeng D; Gao F; Hu K; Jia C; Ibrahim JG
    Stat Med; 2015 Jul; 34(16):2417-26. PubMed ID: 25809924
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.
    Grayling MJ; Dimairo M; Mander AP; Jaki TF
    J Natl Cancer Inst; 2019 Dec; 111(12):1255-1262. PubMed ID: 31218346
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Joint modeling tumor burden and time to event data in oncology trials.
    Shen Y; Anderson A; Sinha R; Li Y
    Pharm Stat; 2014; 13(5):286-93. PubMed ID: 25044957
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Statistical design in phase II clinical trials and its application in breast cancer.
    Perrone F; Di Maio M; De Maio E; Maione P; Ottaiano A; Pensabene M; Di Lorenzo G; Lombardi AV; Signoriello G; Gallo C
    Lancet Oncol; 2003 May; 4(5):305-11. PubMed ID: 12732168
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Application of a new multinomial phase II stopping rule using response and early progression.
    Dent S; Zee B; Dancey J; Hanauske A; Wanders J; Eisenhauer E
    J Clin Oncol; 2001 Feb; 19(3):785-91. PubMed ID: 11157032
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A predictive probability interim design for phase II clinical trials with continuous endpoints.
    Liu M; Dressler EV
    Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Randomized Phase II Trial Designs in Oncology].
    Yoshimura K
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Phase II cancer clinical trials for biomarker-guided treatments.
    Jung SH
    J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
    Chen C; Anderson K; Mehrotra DV; Rubin EH; Tse A
    Contemp Clin Trials; 2018 Jan; 64():238-242. PubMed ID: 28966137
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Continuous endpoints in Bayesian two-stage designs.
    Brutti P; De Santis F; Gubbiotti S; Sambucini V
    J Biopharm Stat; 2016; 26(5):966-77. PubMed ID: 26892274
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Addressing heterogeneity in the design of phase II clinical trials in geriatric oncology.
    Cabarrou B; Sfumato P; Mourey L; Leconte E; Balardy L; Martinez A; Delord JP; Boher JM; Brain E; Filleron T
    Eur J Cancer; 2018 Nov; 103():120-126. PubMed ID: 30223225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.